PDL Aims To Acquire New Royalty Assets Before Current Licenses Expire
This article was originally published in The Pink Sheet Daily
PDL BioPharma has been preparing for the expiry of key patents by making a few hires and reconfiguring its business, with plans to use remaining cash either to purchase new royalty bearing assets or, failing that, to wind up the business.
You may also be interested in...
Can Isis Remain A Platform Company?
With a bulging pipeline, piles of cash, and Big Pharma partners knocking on its doors, Isis believes it is under no pressure to sell its own products. But several factors – including outside pressures and issues intrinsic to Isis’ platform model – are coming into play that may hasten its evolution into an integrated biopharma. And for the first time, Isis management appears open to the possibility.
Deals Of The Week: Mylan/Agila, UCB/Biotie, Jazz/Concert…
Elan peels off assets to attract suitors: First Biogen buys out Elan’s 50% interest in Tysabri, then Royalty Pharma maneuvers to buy out Elan.
Facet Says Yes To Abbott's $720 Million Buyout Offer
The antibody specialist said no to Biogen Idec in December and found a better offer of nearly $10 more a share.